Craig Laferriere
- Courses1
- Reviews1
- School: University of Toronto
- Campus: St. George Campus
- Department: Chemistry
- Email address: Join to see
- Phone: Join to see
-
Location:
Toronto, ON - Dates at University of Toronto: August 2007 - August 2007
- Office Hours: Join to see
Biography
University of Toronto St. George Campus - Chemistry
Consultant in Vaccine Manufacturing and Licensing at CANVAX
Biotechnology
Craig
Laferrière
Mississauga, Ontario, Canada
Management experience at GlaxoSmithKline leading pneumococcal conjugate vaccine team from pre-clinical evaluation to successful PoC in humans.
At Pfizer, launch of new adult indication for Prevnar 13 ™, including advisory boards, presentations at provincial and national vaccine technical committees, which resulted in funded immunization programs in most provinces.
At CANVAX, optimized the design of a Hib conjugate vaccine, which is now licensed in Indonesia under the trade name Pentabio™.
Manufacturing, formulation and preclinical and clinical evaluation of Hib, pneumococccal and meningococcal conjugate, pertussis and combination vaccines.
Multimillion $ budget responsibility for clinical research and trials.
Skilled in Chemistry, Clinical Immunology, and Statistics.
Leadership experience as Medical Advisor, Scientist and Lecturer.
Bilingual (English/French)
Ph.D. Synthetic Organic Chemistry, Université d’Ottawa University, 1990
B.Sc. (Hons., First Class) Chemistry, Carleton University, 1982
Publications: https://www.researchgate.net/profile/Craig_Laferriere
Experience
CANVAX
Consultant in Vaccine Manufacturing and Licensing
International consulting business in vaccine design and manufacturing
Previous Clients: Program for Appropriate Technology in Health, PATH, Seattle, WA
Biovac; Cape Town, South Africa
Responsible for review of scientific reports, advice on management and scientific issues and project planning.Pfizer Canada
Regional Medical Research Specialist and Medical Advisor
Responsible for Therapeutic Strategy, Clinical Research Program Management and Leadership, Therapeutic Area Scientific Expertise, Publication Strategy, Investigator Initiated Research (IIR) Management, Relationship Management, and Operational Effectiveness and Compliance
Successes include:
• Provided inputs to Health Economic analysis of Prevnar 13™ expanded use in Canadian adults
• Prepared epidemiology section of Regulatory submission to Health Canada
• Managed Investigator Initiated Research programs on infectious disease surveillance and an interventional study including First Nations.
• Launched new adult indication for Prevnar13 ™, including hosting advisory boards, and presentation to National Advisory Committee on Immunization and other advisory committees leading to funded immunization programs in most provinces.University of Toronto
Lecturer
Lecture Organic Chemistry
PATH
Consultant
Advised vaccine manufacturers on the preparation of pneumococcal conjugate vaccines.
GlaxoSmithKline
Senior Scientist
• Developed and implemented Canadian vaccines clinical research strategy
• Built and maintained professional relationships with Canadian vaccines key opinion leaders
• Reviewed and managed proposals for academic projects
• Managed Hepatitis A trans-Canadian epidemiology study
• Defended VARILRIX™ varicella vaccine clinical data at the Canadian National Advisory Committee on Immunization (NACI)
• Designed and implemented $1.1 M pediatric vaccine multicentre clinical trial comparing acellular pertussis vaccines
• Managed team of scientists and technicians in immunological and bacteriological research and development.
• GSK representative to the European Bacterial Conjugate Vaccine Network, WHO and PAHO for pneumococcal serology
• Reviewed cancer vaccine intellectual property
• Developed high throughput serological assays for meningitis and pneumococcal vaccines for animal models and clinical studies.
• Secured and defended intellectual property esp. pneumococcal protein vaccines
• Core member of team defending IND applications to US FDA
Education
University of Ottawa / Université d'Ottawa
Ph.D.
Synthetic Organic Chemistry
Thesis on the Synthesis of Sialic Acid Antigens. This objectives of my thesis were to design and synthesize a cancer vaccine based on sialic acid antigens in a variety of forms, and to measure and characterize the immune response to a prototype cancer vaccine in rabbits. Additional objectives centered around NMR characterization and molecular modelling of the 3 dimensional shape of sialic acid antigens.Carleton University
BSc (honours)
Organic Chemistry
University of Toronto
Lecturer
Lecture Organic Chemistry
Publications
Peer reviewed articles, patents, abstracts and PhD thesis are available on Research Gate (click here)
Research Gate
